Abstract: Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene products of a gene of FIG. 2 provide diagnostic, prognostic, prophylactic and/or therapeutic targets for cancer. A gene of FIG. 2 or fragment thereof, its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with a gene product of FIG. 2 can be used in active or passive immunization.
Type:
Grant
Filed:
June 15, 2005
Date of Patent:
January 5, 2010
Assignee:
Agensys, Inc.
Inventors:
Aya Jakobovits, Pia M. Challita-Eid, Mary Faris, Wangmao Ge, Rene S. Hubert, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Arthur B. Raitano, Daniel E. H. Afar
Abstract: The present invention relates to compositions and methods for detecting cancer (e.g., prostate cancer) and for inhibiting metastasis (e.g., associated with prostate cancer). In particular, the present invention provides methods of detecting vimentin expression and secretion and for characterizing cancer (e.g., prostate cancer). In addition, the present invention provides methods for inhibiting metastasis (e.g., of prostate cancer) via altering (e.g., inhibiting) vimentin expression and/or activity.
Type:
Grant
Filed:
November 20, 2006
Date of Patent:
January 5, 2010
Assignee:
The Regents of the University of Michigan
Inventors:
David M. Markovitz, Nirit Mor-Vaknin, Evan T. Keller, Christopher L. Hall, Susan M. Hiniker
Abstract: Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene products of a gene of FIG. 2 provide diagnostic, prognostic, prophylactic and/or therapeutic targets for cancer. A gene of FIG. 2 or fragment thereof, its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with a gene product of FIG. 2 can be used in active or passive immunization.
Type:
Grant
Filed:
June 17, 2005
Date of Patent:
December 8, 2009
Assignee:
Agensys, Inc.
Inventors:
Aya Jakobovits, Pia M. Challita-Eid, Mary Faris, Wangmao Ge, Rene S. Hubert, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Arthur B. Raitano, Daniel E. H. Afar
Abstract: This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing endosialin and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to endosialin-expressing cells as well as in eliciting an immune-effector activity particularly on tumor and neovascular cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer and neovascular cells; and methods of treating cancer and neovascular disease using the antibodies, derivatives and fragments.
Type:
Grant
Filed:
April 24, 2006
Date of Patent:
November 10, 2009
Assignee:
Morphotek, Inc.
Inventors:
Nicholas C. Nicolaides, Luigi Grasso, Philip M. Sass
Abstract: The invention provides novel STAMP2 nucleic acid molecules, polypeptides, antibodies, and modulatory compounds for use in methods of diagnosing, treating, and preventing diseases and conditions of the prostate and testis, such as cancer.
Type:
Grant
Filed:
June 15, 2006
Date of Patent:
November 3, 2009
Assignee:
President and Fellows of Harvard College
Abstract: Inhibitors of the MAPK pathway, including MEK-directed proteases and small molecule inhibitors, are cytotoxic to human melanoma cells in vitro and in vivo via apoptotic mechanisms. These compounds are used to kill melanoma cells and to treat subjects with melanoma, either alone or in combination with other therapeutic modalities.
Type:
Grant
Filed:
June 20, 2005
Date of Patent:
November 3, 2009
Assignee:
Van Andel Research Institute
Inventors:
Han-Mo Koo, Eunmi (Kay) Koo, legal representative, George F. Vande Woude, Nicholas S. Duesbery
Abstract: This invention provides methods for diagnosing prostate cancer, methods for measuring the aggressiveness of prostate cancer, and methods for identifying prostate cancer likely to metastasize. The diagnostic and prognostic assays of this invention include methods involving the antibody-based detection of Pin1 and the amplification of Pin1 RNA. The diagnostic and prognostic assays of this invention may be used in combination with other methods of prostate cancer diagnosis including the PSA test, digital rectal exam, and Gleason prostate tumor grading system.
Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.
Type:
Grant
Filed:
November 22, 2006
Date of Patent:
September 8, 2009
Assignee:
Corixa Corporation
Inventors:
Tongtong Wang, Robert A. Henderson, Teresa M. Foy
Abstract: The invention is an apparatus and method for the treatment of prostate cancer, and involves administering an antibody that specifically binds with prostate antigen.
Type:
Grant
Filed:
October 14, 2004
Date of Patent:
August 25, 2009
Assignee:
AltaRex Medical Corp.
Inventors:
Beatrice Leveugle, Ragupathy Madiyalakan, Antoine A. Noujaim, Birgit C. Schultes
Abstract: A polypeptide having the amino acid sequence as set forth in SEQ ID NO: 2, 4, or 6, a DNA encoding the same, and an antibody against said polypeptide, and the use thereof. The above amino acid sequence has a homology with chondromodulin-I that has an effect of controlling the growth and differentiation of chondrocytes and inhibiting angiogenesis.
Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanized antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
July 28, 2009
Assignee:
Celltech R&D Limited
Inventors:
John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
Abstract: The invention describes the LAGE-1 tumor associated gene, including fragments, allelic variants and splice variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LAGE-1 gene product.
Type:
Grant
Filed:
June 25, 2004
Date of Patent:
July 21, 2009
Assignee:
Ludwig Institute for Cancer Research Ltd.
Abstract: The present invention relates to a screening method for classifying patients and for selecting an effective chemotherapy for the treatment of a patient suffering from non-small-cell lung cancer (NSCLC), based on the use of his levels of BRCA1 expression to predict the outcome of chemotherapy.
Abstract: Polypeptides comprising an unbroken sequence of amino acids from SEQ ID NO: 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1.
Type:
Grant
Filed:
November 26, 1999
Date of Patent:
June 16, 2009
Assignee:
Ludwig Institute for Cancer Research
Inventors:
Lan-Qing Huang, Aline Van Pel, Francis Brasseur, Etienne De Plaen, Thierry Boon
Abstract: A cDNA molecule corresponding to a newly discovered human gene is disclosed. The new gene, which is frequently deleted in liver cancer cells and cell lines, is called the DLC-1 gene. Because the gene is frequently deleted in liver cancer cells, but present in normal cells, it is thought to act as a tumor suppressor. This gene is also frequently deleted in breast and colon cancers, and its expression is decreased or undetectable in many prostate and colon cancers. Also disclosed is the amino acid sequence of the protein encoded by the DLC-1 gene. Methods of using these biological materials in the diagnosis and treatment of hepatocellular cancer, breast cancer, colon cancer, prostate cancer, and adenocarcinomas are presented.
Type:
Grant
Filed:
November 22, 2004
Date of Patent:
May 19, 2009
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Bao-Zhu Yuan, Snorri S. Thorgeirsson, Nicholas Popescu
Abstract: The invention provides the identification and characterization of disease and cancer-associated antigen, RAAG10. The invention also provides a family of monoclonal antibodies that bind to antigen RAAG10, methods of diagnosing and treating various human cancers and diseases that express RAAG10.
Type:
Grant
Filed:
June 19, 2003
Date of Patent:
May 5, 2009
Assignee:
Raven biotechnologies, inc.
Inventors:
Jennie P. Mather, Ronghao Li, Zhuangyu Pan, Penelope E. Roberts
Abstract: The present invention provides novel peptides, nucleic acids, compounds, compositions and methods for regulating apoptosis, and screening methods for identifying same. Regulation of apoptosis is mediated via IAPi-derived proteins, peptide fragments thereof, and nucleic acids encoding same, stimulating/accelerating or downmodulating/suppressing apoptosis. For stimulation/acceleration of apoptosis, the IAPi-derived proteins or peptide fragments thereof comprise RHG and Trp-box amino acid consensus sequences. Stimulation/acceleration results in self-ubiquitination and auto-degradation of an IAP. For downmodulation/suppression of apoptosis, IAPi-derived proteins or peptide fragments thereof comprising either RHG or Trp-box amino acid consensus sequences, or both, failing to stimulate or suppressing self-ubiquitination and auto-degradation of an IAP, result in suppression of apoptosis.
Type:
Grant
Filed:
May 8, 2003
Date of Patent:
March 24, 2009
Assignees:
Rappaport Family Institute for Research in the Medical Sciences, Rockefeller Institute
Inventors:
Hermann Steller, Hyung Don Ryoo, Aaron Ciechanover, Hedva Gonen
Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided.
Type:
Grant
Filed:
March 11, 2005
Date of Patent:
February 24, 2009
Assignees:
Millennium Pharmaceuticals, Inc., UT Board of Regents
Inventors:
Ole Petter Veiby, Robert C. Bast, Jr., Gordon B. Mills, Gabriel N. Hortobagyi
Abstract: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.
Type:
Grant
Filed:
August 6, 2004
Date of Patent:
January 6, 2009
Assignee:
Colora Corporation
Inventors:
Bruno Domon, Ian McCaffery, Vaibhav Narayan, Scott Patterson